Latest Chemotherapy regimens Stories
Younger lymphoma patients given a more intensive chemotherapy regimen combined with rituximab live much longer, and are more than twice as likely to remain in remission 4 years later, compared to patients given standard chemo.
QUEBEC CITY, July 27, 2011 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:Â AEZ) (the "Company") today announced the completion of patient recruitment for the ongoing Phase 3 trial with perifosine in refractory advanced colorectal cancer.
THOUSAND OAKS, Calif., June 24, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that VectibixÂ® (panitumumab) be approved for use in the European Union (EU) in first-line in combination with FOLFOX and in second-line in combination with FOLFIRI in patients who have received first-line fluoropyrimidine-based chemotherapy (excluding...
SEATTLE, April 4, 2011 /PRNewswire/ -- Cell Therapeutics, Inc.
THOUSAND OAKS, Calif., March 30, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) announced today that it has submitted a request to the European Medicines Agency (EMA) for a re-examination of the negative opinion issued in March by the Committee For Medicinal Products for Human Use (CHMP) for the use of Vectibix in combination with chemotherapy for patients with wild-type KRAS metastatic colorectal cancer (mCRC). Amgen believes that Vectibix in combination with chemotherapy provides an important...
THOUSAND OAKS, Calif., March 18, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today issued the following statement: Amgen has received notice that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion for Amgen's application to extend the marketing authorization in Europe for Vectibix(Â®) (panitumumab) to include combination with chemotherapy for the treatment of patients with wild-type KRAS metastatic colorectal cancer...
ORLANDO, Fla., Dec. 5, 2010 /PRNewswire-USNewswire/ -- The next generation of drug therapies and enhanced treatment approaches for various forms of lymphoma are evolving as researchers continue to better understand how these cancers progress.
An antibody loaded with an anti-cancer agent produced complete or partial remissions in 38 percent of patients with relapsed or therapy-resistant Hodgkin lymphoma enrolled in a phase I clinical trial.
A lower dose of radiation used to reduce side effects is not as effective as the regular dose when given with the standard chemotherapy in the treatment of Hodgkin's lymphoma patients with early, intermediate-stage disease.
- The act of sweetening by admixture of some saccharine substance.